间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)是晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)的重要治疗靶点。近几年来,随着多个ALK酪氨酸酶抑制剂(tyrosine kinase inhibitor, TKI)的出现,ALK融合阳性患者的总生存期(overall survival, OS)也在逐渐延长。现报道1例晚期ALK融合阳性NSCLC患者5余年的治疗经过,分析其治疗过程及效果评价,为后续患者的治疗提供经验。. This evidence concerns the gene ALK and non-small cell lung carcinoma.